Table 4 Clinical trials evaluating WEE1/PKMYT1 inhibitor in monotherapy or in combination for cancer therapy

NCT02610075

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

S

AZD1775

C

1

NCT03668340

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma

S

AZD1775

R

2

NCT02482311

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

S

AZD 1775

C

1

NCT02207010

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

S

AZD1775

NA

1

NCT03315091

Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours

S

AZD1775

C

1

NCT01748825

AZD1775 for Advanced Solid Tumors

S/H

AZD1775

ANR

1

NCT02511795

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

S

AZD1775 + Olaparib

C

1

NCT03313557

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

S

AZD1775

C

1

NCT02593019

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

S

AZD1775

NA

2

NCT02688907

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

S

AZD1775

T

2

NCT02087176

A Placebo Controlled Study Comparing AZD1775 + Docetaxel Versus Placebo + Docetaxel to Treat Lung Cancer

S

AZD1775 + Docetaxel

T

2

NCT03012477

CISPLATIN + AZD-1775 In Breast Cancer

S

AZD1775 + Cisplatin

ANR

2

NCT02341456

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

S

AZD1775 + Carboplatin or Paclitaxel

C

1

NCT02791919

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

H

AZD1775 + Cytarabine or Filgrastim or Fludarabine Phosphate

W

1

NCT02513563

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

S

AZD1775 + Carboplatin or Paclitaxel

R

2

NCT03718143

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

H

AZD1775 + Cytarabine

T

2

NCT02585973

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

S

AZD1775 + Cisplatin + Radiation

R

1

NCT02087241

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

S

AZD1775 + pemetrexed or carboplatin

T

2

NCT02381548

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

H

AZD1775 + Belinostat

T

1

NCT03333824

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

S

AZD1775

C

1

NCT02906059

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

S

AZD1775 + Irinotecan

R

1

NCT02037230

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

S

AZD1775 + Gemcitabine+ Radiation Therapy

C

1,2

NCT02617277

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

S

AZD1775 + Durvalumab

ANR

1

NCT02666950

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

H

AZD1775 + Cytarabine

C

2

NCT01047007

A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)

S

AZD1775 + 5-FU or 5-FU/CDDP

T

1

NCT01164995

Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

S

AZD1775 + carboplatin

NA

2

NCT02448329

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

S

AZD1775 + paclitaxel

R

2

NCT02508246

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

S

AZD1775 + Cisplatin + Docetaxel

C

1

NCT03253679

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

S

AZD1775

R

2

NCT01076400

A Study of MK-1775 in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

S

AZD1775 + Topotecan or Cisplatin

T

1,2

NCT02196168

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

S

AZD1775 +Cisplatin

T

2

NCT02101775

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

S

AZD1775 + Gemcitabine

ANR

2

NCT03028766

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

S

AZD1775 + Cisplatin + Radio therapy

ANR

1

NCT01357161

A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

S

AZD1775 + paclitaxel + carboplation

C

2

NCT03284385

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

S

AZD1775

R

2

NCT00648648

A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

S

AZD1775 + Gemcitabine or Cisplatin or Carboplatin

C

1

NCT02194829

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

S

AZD-1775 + Gemcitabine + paclitaxel

ANR

1,2

NCT02576444

Olaparib Combinations

S

AZD1775 + olaparib

ANR

2

NCT04197713

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

S

AZD1775 + olaparib

ANR

1

NCT01922076

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

S

AZD1775 + Radiation Therapy

ANR

1

NCT03579316

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

S

AZD1775 + olaparib

R

2

NCT02095132

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

S

AZD1775 + Irinotecan or Irinotecan Hydrochloride

R

1,2

NCT03345784

Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer

S

AZD1775 +Cisplatin + Radiation (External Beam Radiation Therapy)

R

1

NCT01849146

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

S

AZD1775 + Radiation Therapy + Temozolomide

R

1

NCT02937818

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

S

AZD1775 + carboplatin

ANR

2

NCT02546661

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

S

AZD1775 + Durvalumab

ANR

1

NCT02659241

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

S

AZD1775

R

1

NCT02272790

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

S

AZD1775 + Paclitaxel or Carboplatin or Gemcitabine or pegylated liposomal doxorubicin

ANR

2

NCT02813135

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

S/H

AZD1775 + carboplatin

R

1,2

NCT03330847

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

S

AZD1775 + olaparib

R

2

NCT01827384

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

S

AZD1775 + carboplatin

R

2

NCT02465060

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

S/H

AZD1775

R

2